KLRS - מכפיל EV/EBITDA Kalaris Therapeutics

Kalaris Therapeutics Inc (KLRS) is implementing advanced antibodies and gene therapies to combat ocular pathologies, aiming for a large-scale expansion of its product portfolio to achieve sector dominance. The confirmed price history on the EV/EBITDA chart at GURU.Markets is recorded at 0.00. The project's success relies on the flawless transportation of biomaterials under extreme cold, ensuring the integrity of the therapy during delivery to medical centers.
פילוחים אנליטיים של חברת Kalaris Therapeutics Inc

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation and amortization, allowing for an assessment of asset value relative to the ability to generate cash flow. For Kalaris Therapeutics Inc (KLRS), which is in the clinical trial stage without revenue, this calculation reveals a critical gap between the company's valuation and negative operating leverage, clearly reflecting the EV/EBITDA multiple level of a capital-intensive enterprise.